In the last week, the United States market has stayed flat, although it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that might be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|---|---|---|---|
| Seagate Technology Holdings (STX) |
$673.64 |
$1330.31 |
49.4% |
| Q2 Holdings (QTWO) |
$50.75 |
$97.97 |
48.2% |
| First Merchants (FRME) |
$40.44 |
$77.39 |
47.7% |
| FinWise Bancorp (FINW) |
$15.55 |
$29.71 |
47.7% |
| FB Financial (FBK) |
$54.07 |
$103.19 |
47.6% |
| Chemung Financial (CHMG) |
$66.41 |
$127.22 |
47.8% |
| BillionToOne (BLLN) |
$75.05 |
$147.13 |
49% |
| AppLovin (APP) |
$446.35 |
$858.66 |
48% |
| Alnylam Pharmaceuticals (ALNY) |
$309.49 |
$610.25 |
49.3% |
| Aldeyra Therapeutics (ALDX) |
$1.52 |
$3.02 |
49.6% |
Let's review some notable picks from our screened stocks.
Seagate Technology Holdings
Overview:Seagate Technology Holdings plc provides data storage technology and infrastructure solutions globally, with operations in Singapore, the United States, the Netherlands, and other international markets, and has a market cap of $144.12 billion.
Operations:Seagate's revenue primarily comes from its data storage technology and infrastructure solutions offered across various international markets, including Singapore, the United States, and the Netherlands.
Estimated Discount To Fair Value:49.4%
Seagate Technology Holdings is trading significantly below its estimated future cash flow value, suggesting it may be undervalued. The company reported strong earnings growth with Q3 sales of US$3.11 billion and net income of US$748 million, up from the previous year. Despite high debt levels and recent insider selling, Seagate's revenue and earnings are forecast to outpace the market significantly, driven by innovative product offerings like the Mozaic 4+ platform.
TTM Technologies
Overview:TTM Technologies, Inc. is a company that manufactures and sells mission systems, RF components, RF microwave/microelectronic assemblies, and printed circuit boards (PCBs) and substrates across the United States, Taiwan, and internationally with a market cap of $14.28 billion.
Operations:TTM Technologies generates revenue through its production and sale of mission systems, RF components, RF microwave/microelectronic assemblies, and printed circuit boards (PCBs) and substrates in various global markets.
Estimated Discount To Fair Value:20.2%
TTM Technologies is trading significantly below its estimated future cash flow value, indicating potential undervaluation. Recent earnings showed robust growth, with Q1 sales at US$845.98 million and net income of US$49.99 million, both up from the previous year. Despite recent insider selling and share price volatility, TTM's earnings are forecast to grow substantially faster than the market average, supported by expected revenue growth that outpaces the broader U.S. market.
AbbVie
Overview:AbbVie Inc. is a research-based biopharmaceutical company involved in the research and development, manufacturing, commercialization, and sale of medicines and therapies globally, with a market cap of approximately $360.63 billion.
Operations:AbbVie's revenue primarily comes from its operations in developing, manufacturing, and selling a range of pharmaceutical products and therapies worldwide.
Estimated Discount To Fair Value:46.8%
AbbVie is trading substantially below its estimated future cash flow value, suggesting potential undervaluation. Despite a decline in net income to US$695 million for Q1 2026, AbbVie's sales increased to US$15 billion from the previous year. The company's earnings are forecasted to grow significantly faster than the U.S. market average over the next three years. However, AbbVie's dividend is not well covered by earnings, and recent insider selling may warrant attention from investors considering cash flow-based valuation opportunities.
-
The analysis detailed in our AbbVie growth report hints at robust future financial performance.
-
Click here to discover the nuances of AbbVie with our detailed financial health report.
Turning Ideas Into Actions
-
Delve into our full catalog of 150 Undervalued US Stocks Based On Cash Flows here.
-
Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
-
Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Contemplating Other Strategies?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include STX TTMI and ABBV .
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
